NCT02532049View on ClinicalTrials.gov

A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 12, 2015

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions
Malaria
Interventions
BIOLOGICAL

ChAd63 Pfs25-IMX313

BIOLOGICAL

MVA Pfs25-IMX313

Trial Locations (2)

OX3 7LE

CCVTM, University of Oxford, Churchill Hospital, Oxford

SO16 6YD

NIHR Wellcome Trust Clinical Research Facility, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02532049 - A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313 | Biotech Hunter | Biotech Hunter